Sure, Bit Bio got some significant cash for its cell coding work. But it’s the insiders who are backing them that will garner the attention
Mark Kotter’s synthetic biology team at Bit Bio has already won lots of local recognition in the UK for its tech for precision reprogramming of stem cells at an industrial scale. Now they have a jolt of cash from some marquee US investors to fuel the work and drive some added global panache for the biotech’s profile.
The money — $41.5 million — isn’t likely to stir much attention these days as billions in cash continue to course through the industry. These investor names, though, as well as their interest in cell therapy 2.0, should create a tingle of excitement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,600+ biopharma pros reading Endpoints daily — and it's free.